Human Amniotic Membrane as Adjuvant Therapy in Medication-Related Osteonecrosis of the Jaw: A Scoping Review
Solimano S¹, Taliercio F², Osses F³*, Alfaro J4, Caneo S5, Salinas F6
¹DDS, Oral and Maxillofacial Surgeon, Armada de Chile, Valparaíso, Chile.
²DDS, Oral and Maxillofacial Surgeon, Universidad de Valparaíso, Valparaíso, Chile.
³DDS, Universidad de Valparaíso, Valparaíso, Chile.
4DDS, Universidad de Antofagasta, Antofagasta, Chile.
5DDS, Universidad de Valparaíso, Valparaíso, Chile.
6DDS, Universidad Andrés Bello, Valparaíso, Chile.
*Corresponding Author: Fernanda Osses, DDS, Universidad de Valparaíso, Valparaíso, Chile.
https://doi.org/10.58624/SVOADE.2026.07.020
Received: May 13, 2026
Published: June 01, 2026
Citation: Solimano S, Taliercio F, Osses F, Alfaro J, Caneo S, Salinas F. Human Amniotic Membrane as Adjuvant Therapy in Medication-Related Osteonecrosis of the Jaw: A Scoping Review. SVOA Dentistry 2026, 7:3, 152-158. doi: 10.58624/SVOADE.2026.07.020
Abstract
Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized by progressive destruction of the maxillary and mandibular bones in patients receiving antiresorptive or antiangiogenic agents. Despite evolving clinical guidelines, its management remains controversial and non standardized. Human amniotic membrane (HAM) has emerged as a promising adjuvant therapy due to its immunomodulatory, anti-inflammatory, and regenerative properties.
Objective: To identify and synthesize available evidence on the effectiveness of HAM as an adjuvant treatment in promoting wound healing in patients diagnosed with MRONJ.
Methods: A scoping review was conducted following the PRISMA-ScR framework. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science using MeSH terms and free-text keywords including “amniotic membrane,” “amnion,” “bisphosphonate-associated osteonecrosis,” and “medication related osteonecrosis of the jaw,” combined with Boolean operators. Searches were limited to primary human studies published within the past five years.
Results: A total of 25 records were identified; after deduplication and screening, 3 primary studies were included comprising a total of 39 patients across various MRONJ stages. Across all studies, 83.8% of patients achieved complete mucosal wound closure, and 84.6% reported a significant reduction in pain perception. No adverse events, recurrences, or infectious complications were reported.
Conclusions: HAM represents a viable, versatile, and effective adjuvant intervention in the surgical management of MRONJ. It promotes soft-tissue healing, reduces pain and infection, and favorably impacts patient prognosis and quality of life. Randomized controlled trials with larger samples and standardized protocols are warranted.
Keywords: Medication-Related Osteonecrosis of the Jaw; Amniotic Membrane; Adjuvant Therapy; Wound Healing; Scoping Review.
